

***Fiscal Year 2024 Department of Defense Ovarian Cancer Research Program (OCRP)
Reference Table of Award Mechanisms and Submission Requirements***

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadline |
|--|---|--|--|---|
| <p>Clinical Trial Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524OCRPCTA</p> | <p>Independent investigators at all academic levels.</p> | <p>Supports rapid implementation of clinical trials with the potential to have a significant impact on ovarian cancer.</p> <ul style="list-style-type: none"> • Proposed projects may range from small, proof-of-concept trials through large-scale, definitive trials, including early-phase or pilot clinical trials (phase 0, 1, or 1/2). • Preliminary data are required. Larger, more-definitive clinical trials, including expansion of previous promising pilot trials, must include preliminary data with respect to safety in an ovarian cancer population. | <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$2,000,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. | <p>Pre-Application (Letter of Intent): June 3, 2024 5:00 p.m. Eastern time</p> <p>Application: August 6, 2024 11:59 p.m. Eastern time</p> |
| <p>Clinical Trial Translational Endpoints Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524OCRPCTTERA</p> | <p>Investigators at or above the level of Assistant Professor (or equivalent).</p> | <p>Supports correlation of clinical trial-related data with clinical outcomes or responses to therapies. Correlative studies may be associated with a past, ongoing, or future clinical trial in order to associate various factors (genetic, biochemical, environmental and others) with initiation, progression, metastasis, recurrence, prognosis, diagnosis or effect of intervention on ovarian cancer outcomes.</p> <ul style="list-style-type: none"> • Projects associated with randomized phase 2 or 3 trials are encouraged. • Inclusion of clinical trialist as a collaborator is required. • Clinical trials are not allowed. <i>The award may not be used to directly support a clinical trial.</i> • Studies that are strictly animal research will not be considered for this award mechanism. | <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1,000,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. | <p>Pre-Application (Letter of Intent): June 3, 2024 5:00 p.m. Eastern time</p> <p>Application: August 6, 2024 11:59 p.m. Eastern time</p> |
| <p>Investigator-Initiated Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524OCRPIIRA</p> | <p>Investigators at or above the level of Assistant Professor (or equivalent).</p> <p>Partnering Principal Investigator Option: Up to two investigators may collaborate on a single application, each of whom will be recognized as a PI and receive a separate award.</p> | <p>Supports high-impact research that addresses a critical need and has the potential to make an important contribution to ovarian cancer or patient/survivor care.</p> <ul style="list-style-type: none"> • Research aimed at extending the lives of advanced state and recurrent patients is encouraged. • If cell lines or animals are used, justification for use is required. • Preliminary data are required. • Clinical trials are not allowed. <p><i>Pre-application is required; application submission is by invitation only.</i></p> | <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is: <ul style="list-style-type: none"> ○ \$1,000,000 for direct costs for a single PI. ○ \$1,200,000 for direct costs for Partnering PIs ○ Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. ○ The maximum period of performance is 4 years. | <p>Pre-Application (Preproposal): May 14, 2024 5:00 p.m. Eastern time</p> <p>Application: August 6, 2024 11:59 p.m. Eastern time</p> |

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadline |
|---|---|---|--|--|
| <p>Ovarian Cancer Academy – Early-Career Investigator Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524OCRPOCAECI</p> | <p>Early-Career Investigator: Investigators must be within 5 years of their last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.) or equivalent at the time of full application submission deadline. A letter attesting to eligibility is required.</p> <p>Designated Mentor: A Designated Mentor who is an experienced ovarian cancer researcher with ovarian cancer funding is required. The Designated Mentor is not required to be at the same institution as the Early-Career Investigator, ECI.</p> | <p>Supports the addition of new ECIs to the unique, interactive virtual Ovarian Cancer Academy, which provides intensive mentoring, national networking, collaborations, and a peer group for junior faculty interested in basic and translational research.</p> <ul style="list-style-type: none"> • ECIs whose ability to commit to conducting ovarian cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply. • A Designated Mentor may only mentor one ECI. • Preliminary data are required. • Clinical trials are not allowed. • <i>Investigators may apply to both ECI funding opportunities offered by the OCRP (i.e., Ovarian Cancer Academy – Early-Career Investigator Award and Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award) during the same fiscal year but may not accept awards from both funding opportunities. Investigators may not participate in both the Ovarian Cancer Academy and the Ovarian Cancer Clinical Trial Academy as an ECI at the same time.</i> <p>Pre-application is required; application submission is by invitation only.</p> | <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$725,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. | <p>Pre-Application (Preproposal): May 14, 2024 5:00 p.m. Eastern time</p> <p>Application: August 6, 2024 11:59 p.m. Eastern time</p> |
| <p>Ovarian Cancer Academy – Leadership Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524OCRPOCALA</p> | <p>The Dean and Assistant Dean must be established ovarian cancer researchers, have past or present ovarian cancer research funding, and have a record of ovarian cancer publications.</p> | <p>The Ovarian Cancer Academy leadership team consists of an academy Dean and Assistant Dean. This award supports building an interactive academy led by visionary individuals who are established ovarian cancer researchers. This academy will focus on developing ECIs in ovarian cancer in a collaborative research and career development environment.</p> <ul style="list-style-type: none"> • The Academy Dean and the Assistant Dean are responsible for facilitating regular interactive communication among all Academy members. • Proof of principle is requested. | <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1,750,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. | <p>Pre-Application (Letter of Intent): June 3, 2024 5:00 p.m. Eastern time</p> <p>Application: August 6, 2024 11:59 p.m. Eastern time</p> |
| <p>Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions | <p>Early-Career Investigator: Investigators must be within 12 years of their last postdoctoral research position (Ph.D.), clinical fellowship (M.D.), or</p> | <p>Supports the first cohort of ECIs to the new virtual Ovarian Cancer Clinical Trial Academy, which aims to produce the next generation of ECIs in clinical trial research and effective treatments and cures for ovarian cancer.</p> <ul style="list-style-type: none"> • Research will support translational research and small-scale, early phase clinical trials in ovarian cancer. | <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1,000,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. | <p>Pre-Application (Letter of Intent): June 24, 2024 5:00 p.m. Eastern time</p> <p>Application: August 6, 2024 11:59 p.m. Eastern time</p> |

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadline |
|---|---|---|--|--|
| <p>Grants.gov Funding Opportunity Number: HT942524OCRPOCCTAECI</p> | <p>equivalent at the time of full application submission deadline. A letter attesting to eligibility is required.</p> <p>Designated Mentor: A Designated Mentor who is an independent, established clinical trialist with a balanced portfolio of clinical trial experience is required. The Designated Mentor is not required to be at the same institution as the ECI.</p> | <ul style="list-style-type: none"> • ECIs whose ability to commit to conducting ovarian cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply. • Experience in ovarian cancer research must be demonstrated by the ECI or the Designated Mentor. • Preliminary data are required. • Clinical trials are allowed. • <i>Investigators may apply to both ECI funding opportunities offered by the OCRP (i.e., Ovarian Cancer Academy – Early-Career Investigator Award and Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award) during the same fiscal year but may not accept awards from both funding opportunities. Investigators may not participate in both the Ovarian Cancer Academy and the Ovarian Cancer Clinical Trial Academy as an ECI at the same time.</i> | <ul style="list-style-type: none"> • The maximum period of performance is 4 years. | |
| <p>Pilot Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942524OCRPPA</p> | <p>Investigators at the level of postdoctoral fellow or clinical fellow (or equivalent).</p> | <p>Supports innovative, high-risk/high-reward research in ovarian cancer that could ultimately lead to critical discoveries or major advancements that will drive the field forward.</p> <ul style="list-style-type: none"> • Innovation is an important review criterion. • The goal is to develop preliminary data; thus, preliminary data are not required, but are allowed. • Research aimed at extending the lives of advanced-state and recurrent patients is encouraged. • Clinical trials are not allowed. <p><i>Pre-application is required and blinded; application submission is by invitation only.</i></p> | <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$300,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 2 years. | <p>Pre-Application (Preproposal): May 14, 2024 5:00 p.m. Eastern time</p> <p>Application: August 6, 2024 11:59 p.m. Eastern time</p> |